Cargando…

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has been available for the treatment of moderate to severe psoriasis and psoriatic arthritis since February 2015 in Japan. Because there was a time gap after the previous approval of biologics for psoriatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujita, Hideki, Ohtsuki, Mamitaro, Morita, Akimichi, Nagao, Ryuji, Seko, Noriko, Matsumoto, Kazuko, Tani, Yumiko, Terui, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894540/ https://www.ncbi.nlm.nih.gov/pubmed/33099791 http://dx.doi.org/10.1111/1346-8138.15655

Ejemplares similares

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Improved quality of life of patients with generalized pustular psoriasis in Japan: A cross‐sectional survey
por: Hayama, Koremasa, et al.
Publicado: (2020)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report
por: Lu, Jiajing, et al.
Publicado: (2020)

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Risk Factors for the Development of Psoriasis
por: Kamiya, Koji, et al.
Publicado: (2019)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
por: Okubo, Yukari, et al.
Publicado: (2021)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2019)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris
por: Morita, Akimichi, et al.
Publicado: (2022)

Altered Lipid Metabolism in Blood Mononuclear Cells of Psoriatic Patients Indicates Differential Changes in Psoriasis Vulgaris and Psoriatic Arthritis
por: Wójcik, Piotr, et al.
Publicado: (2019)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ea57kdvq71nkrq9q7kgoh7p81p